<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?</h2>
    <div class="badge">2025-09-15T15:08:00+00:00</div>
    <ul>
      <li>In 2025, Lilly expects to record revenues in the range of $60.0 billion to $62.0 billion, indicating an impressive year-over-year growth of more than 30% We believe that LLY has solid growth prospects and a promising por</li>
<li>Mounjaro and Zepbound account for around 50% of the company’s total revenues.</li>
<li>Lilly’s stock is up 18% since the second-quarter results, easing some of the recent negative sentiment.</li>
<li>Competition Heating Up in the Obesity Space The obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs, which means fierce competition is inevitable.</li>
<li>In 2025, it announced three M&amp;A deals.</li>
<li>LLY’s Stock Price, Valuation and Estimates Lilly’s stock has declined 2.2% so far this year compared with the industry’s decrease of 0.2%.</li>
<li>In the ATTAIN-2 study in obese adults with type II diabetes, the highest dose (36 mg) of orforglipron delivered a weight loss of up to an average of 22.9 pounds or 10.5%.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?\n• In 2025, Lilly expects to record revenues in the range of $60.0 billion to $62.0 billion, indicating an impressive year-over-year growth of more than 30% We believe that LLY has solid growth prospects and a promising por\n• Mounjaro and Zepbound account for around 50% of the company’s total revenues.\n• Lilly’s stock is up 18% since the second-quarter results, easing some of the recent negative sentiment.\n• Competition Heating Up in the Obesity Space The obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs, which means fierce competition is inevitable.\n• In 2025, it announced three M&amp;A deals.\n• LLY’s Stock Price, Valuation and Estimates Lilly’s stock has declined 2.2% so far this year compared with the industry’s decrease of 0.2%.\n• In the ATTAIN-2 study in obese adults with type II diabetes, the highest dose (36 mg) of orforglipron delivered a weight loss of up to an average of 22.9 pounds or 10.5%." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/lilly-moves-past-50-day-150800320.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>